{"id":252044,"date":"2020-06-22T00:00:00","date_gmt":"2020-06-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcv0046-biopharma-peripheral-arterial-disease-epidemiology-asia\/"},"modified":"2026-03-31T10:44:58","modified_gmt":"2026-03-31T10:44:58","slug":"epidcv0046-biopharma-peripheral-arterial-disease-epidemiology-asia-pacific","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0046-biopharma-peripheral-arterial-disease-epidemiology-asia-pacific\/","title":{"rendered":"Peripheral Arterial Disease &#8211; Epidemiology &#8211; Asia-Pacific"},"content":{"rendered":"<p><abbr title=\"Decision Resources Group\">DRG<\/abbr> Epidemiology\u2019s coverage of peripheral arterial disease (<abbr title=\"peripheral arterial disease\">PAD<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr title=\"peripheral arterial disease\">PAD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years; in other countries, forecasts cover a 10-year period. In addition to forecasting prevalent patient populations, we calculate the number of drug-treatment opportunities in specific lines of therapy in the mature pharmaceutical markets.<\/p>\n<p><abbr title=\"Decision Resources Group\">DRG<\/abbr> Epidemiology\u2019s <abbr title=\"peripheral arterial disease\">PAD<\/abbr> forecast will answer the following questions:<\/p>\n<ul>\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with <abbr title=\"peripheral arterial disease\">PAD<\/abbr>?<\/li>\n<li>Of all people with <abbr title=\"peripheral arterial disease\">PAD<\/abbr>, how many in each country have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"peripheral arterial disease\">PAD<\/abbr>, how many in the mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"peripheral arterial disease\">PAD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the <abbr title=\"Decision Resources Group\">DRG<\/abbr> Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph\u00a0of the patient flow between or within different disease states for the mature pharmaceutical markets. These patient flows are provided at the regional level but may be requested for any specific country or forecast year.<\/p>\n<p><abbr title=\"Decision Resources Group\">DRG<\/abbr> Epidemiology provides at least ten years of forecast data for the following <abbr title=\"peripheral arterial disease\">PAD<\/abbr> patient populations:<\/p>\n<ul>\n<li>Total prevalent cases.<\/li>\n<li>Diagnosed prevalent cases.<\/li>\n<\/ul>\n<p>\u2026 and many more (details available on request).<\/p>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-252044","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-peripheral-arterial-disease","biopharma-product-epidemiology","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252044\/revisions"}],"predecessor-version":[{"id":284542,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252044\/revisions\/284542"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=252044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}